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Microglia are involved in physiological as well as neuropathological processes in the
central nervous system (CNS). Their functional states are often referred to as M1-like
and M2-like activation, and are believed to contribute to neuroinflammation-mediated
neurodegeneration or neuroprotection, respectively. Parkinson’s disease (PD) is one
the most common neurodegenerative disease and is characterized by the progressive
loss of midbrain dopaminergic (mDA) neurons in the substantia nigra resulting in
bradykinesia, tremor, and rigidity. Interleukin 4 (IL4)-mediated M2-like activation of
microglia, which is characterized by upregulation of alternative markers Arginase 1 (Arg1)
and Chitinase 3 like 3 (Ym1) has been well studied in vitro but the role of endogenous IL4
during CNS pathologies in vivo is not well understood. Interestingly, microglia activation
by IL4 has been described to promote neuroprotective and neurorestorative effects,
which might be important to slow the progression of neurodegenerative diseases.
In the present study, we addressed the role of endogenous and exogenous IL4
during MPP+-induced degeneration of mDA neurons in vitro and further addressed
the impact of IL4-deficiency on neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model of PD in vivo. Our results clearly demonstrate
that exogenous IL4 is important to protect mDA neurons in vitro, but endogenous
IL4 seems to be dispensable for development and maintenance of the nigrostriatal
system as well as MPTP-induced loss of TH+ neurons in vivo. These results underline
the importance of IL4 in promoting a neuroprotective microglia activation state and
strengthen the therapeutic potential of exogenous IL4 for protection of mDA neurons
in PD models.
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INTRODUCTION
Microglia are the resident immune cells of the central nervous system (CNS), and thus are involved
in a plethora of physiological as well as neuropathological conditions (Prinz and Priller, 2014).
Similar to peripheral macrophages (Mosser, 2003; Gordon and Martinez, 2010), the functions of
microglia are regulated by various endogenous and exogenous stimuli and their functional states
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are referred to as M1-like and M2-like activation (Prinz and
Priller, 2014). M1-like microglia activation induced by Th1
cytokines, such as IFNγ or the bacterial lipopolysaccharide
(LPS), induces secretion of pro-inflammatory cytokines and
reactive oxygen species, which are believed to contribute to
neuroinflammation-mediated neurodegeneration (Block et al.,
2007). M2-like microglia activation is induced by the Th2
cytokines Interleukin 4 (IL4) and Interleukin 13 (IL13) and
characterized by upregulation of alternative activation markers
Arginase-1 (Arg1) and Chitinase 3 like 3 (Ym1) (Colton
and Wilcock, 2010; Zhou et al., 2012). IL4-induced M2-like
microglia/macrophage activation has been described to exert
neuroprotective effects in mouse models for spinal cord injury
(Francos-Quijorna et al., 2016), cerebral ischemia (Liu et al.,
2016) and multiple sclerosis (Butti et al., 2008). Next to the
abovementioned CNS pathologies, M2-like microglia activation
has been further described in animal models of Parkinson’s
disease (PD) and has been associated with reduced progression
and disease severity (Moehle and West, 2015). PD is the second
most common neurodegenerative disease and is characterized by
the progressive loss of midbrain dopaminergic (mDA) neurons
in the substantia nigra (SN) (Jellinger, 2001). This loss of
mDA neurons results in a subsequent reduction in striatal
dopamine (DA) levels, which is responsible for the classical
clinical symptoms such as resting tremor, bradykinesia and
rigidity (Jankovic, 2008). Although the IL4-mediated activation
of microglia, which is characterized by upregulation of alternative
markers Arginase 1 (Arg1) and Chitinase 3 like 3 (Ym1) has been
well studied in vitro (Zhou et al., 2012), the role of endogenous
IL4 during CNS pathologies in vivo is not well understood.
IL4-deficient mice have been reported to develop normally,
without showing morphological abnormalities, reduced secretion
of IL5 and IL10, as well as an impaired expression of IL4-
dependent IgE and IgG1 (Metwali et al., 1996). Moreover, loss
of IL4 resulted in decreased neuron-microglia communication
via the CD200-CD200R ligand-receptor pair and increased
neuroinflammatory responses after LPS application (Lyons
et al., 2009). CNS-derived IL4 has been further shown to
play important roles during regulation of microglia/macrophage
activation in the EAE model for multiple sclerosis (Ponomarev
et al., 2007). In the present study, we have analyzed the
role of endogenous and exogenous IL4 during MPP+-induced
degeneration of mDA neurons in vitro and further addressed
the impact of IL4-deficiency on neurodegeneration in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse
model of PD in vivo. Our results clearly demonstrate that
IL4 is important to protect mDA neurons in vitro but seems
to be dispensable for MPTP-induced loss of TH+ neurons
in vivo.
MATERIALS AND METHODS
Animals
C57BL/6 mice were housed at 22 ± 2◦C under a 12 h
light/dark cycle with ad libitum access to food and water.
C57BL/6-IL4tm1Nnt/J mice as described by Metwali et al. (1996)
were obtained from the Jackson Laboratory (via Charles River,
Germany) and are from now on referred to as IL4 KO mice. All
animal procedures were conducted in strict accordance with the
German federal animal welfare law, local ethical guidelines and
have been approved by the animal experimentation committee of
the University of Freiburg and the Regierungspräsidium Freiburg
(G-11/77 [MPTP], X-12/01D [E14 mDA neurons], X-12/02D
[primary microglia]).
MPTP-Induced Neurodegeneration
Adult (10–12 weeks) male wild type (WT) and IL4 KO mice were
intraperitoneally injected with 20 mg/kg MPTP hydrochloride
(Sigma-Aldrich) dissolved in 0.2 ml phosphate-buffered saline
(PBS) once a day for three consecutive days as previously
described (Machado et al., 2016a). Mice were sacrificed after 1,
2, 7, and 90 days after injections. PBS only injected mice served
as controls. A total of 64 mice were used throughout this study
(WT n = 37, IL4 KO n = 27). All procedures involving MPTP
were conducted in strict accordance with published safety and
handling guidelines (Przedborski et al., 2001).
Primary Microglia Cultures
Primary microglia cultures were generated as previously
described (Spittau et al., 2013). Briefly, blood vessels and
meninges were removed from brains of P0/P1 C57BL/6 mice
(Janvier) and brains were washed in ice-cold Hank’s BSS (Gibco,
Germany). After enzymatic dissociation with Trypsin-EDTA
(Gibco, Germany) for 15 min at 37◦C, an equal volume of
fetal calf serum (FCS, Gibco, Germany) together with DNase
(Roche, Mannheim, Germany) at a final concentration of
0.05 mg/ml was added. Cells were dissociated using wide-
and narrow-bored polished Pasteur pipettes. Finally, cells were
centrifuged and resuspended in DMEM/F12 medium (Gibco,
Germany) containing 10% FCS and 1% penicillin/streptomycin
(Invitrogen). Cell suspensions from 2–3 brains were plated
on poly-D-lysine-coated (Sigma-Aldrich, Schnelldorf, Germany)
75 cm2 culture flasks. Cultures were kept in a 5% CO2/95%
humidified atmosphere at 37◦C. After 10–14 days in culture,
microglia were shaken off (250–300 rpm for 1 h) from adherent
astrocytes and were plated according to the experimental
purposes.
E14 Ventral Midbrain-Derived
Neuron-Enriched and Mixed Neuron-Glia
Cultures
Neuron-enriched and mixed neuron-glia cultures from
embryonic day 14 (E14) ventral midbrains of NMRI mice
(Charles River Laboratories Inc.) were generated as described
previously (Machado et al., 2016b). Dissected ventral midbrains
were dissociated using Trypsin-EDTA (Gibco) for 15 min at
37◦C. DNase (Roche) was added to a final concentration of
0.05 mg/ml and after gentle trituration using fire-polished
Pasteur pipettes, cell suspensions were centrifuged at 1000 × g
for 4 min. Cell pellets were resuspended in DMEM/F12
medium (Gibco) containing either 10% FCS, 10% horse
serum (HS) and 1% penicillin/streptomycin (Invitrogen)
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to obtain mixed neuron-glia cultures, or N2 supplement
(Invitrogen) and 1% penicillin/streptomycin (Invitrogen) to
obtain neuron-enriched cultures. Both cultures were plated
on poly-D-lysine-coated (Sigma-Aldrich) glass coverslips
(12 mm diameter) at a density of 1–2 midbrains/coverslip.
On day in vitro 1 (DIV1) medium was refreshed and mixed
neuron-glia cultures were maintained for additional 7 days
to yield mature cultures. Neuron-enriched cultures were
treated from DIV1 according to the experimental design.
Cultures were kept in a 5% CO2/95% humidified atmosphere
at 37◦C. MPP+ (Sigma-Aldrich) treatments were performed
as described recently (Spittau et al., 2012). IL4 (10 ng/ml) and
IGF-1 (50 ng/ml) were obtained from Peprotech (Germany)
and prepared and dissolved according to the manufacturer’s
instructions.
Neutralization of IL4 In vitro
Blocking of IL4 in E14 ventral midbrain mixed neuron-glia
cultures was achieved using a IL4 neutralizing antibody (IL4nAB)
obtained from Ebiosciences (Frankfurt, Germany). Functionality
and optimal concentrations were confirmed in IL4-treated
primary microglia cultures and the IL4 nAB was used in mixed
neuron-glia cultures at a dilution of 1:50.
RNA Isolation and Reverse Transcription
Total RNA was isolated from primary microglia using
TRIzol reagent (Invitrogen, Karlsruhe, Germany) according
to manufacturer’s instructions. RNAs from SN and caudate
putamen (CPu) were isolated after dissection and transfer to
RNA later (Ambion). Tissues were homogenized in peqGOLD
TriFast (PeqLab) using a Precellys 24 homogenizer (PeqLab).
RNA concentration and quality was determined using the
NanoDrop 2000 (Thermo Scientific, Germany). 1 µg RNA
from each sample was reverse transcribed to cDNA using
RevertAid (Fermentas, St. Leon-Rot, Germany) according to the
manufacturer’s instructions.
Semiquantitative and Quantitative
RT-PCR
Semiquantitative RT-PCR (Eppendorf Mastercycler, Eppendorf,
Germany) was performed using the PCR Red-Mastermix 2x
(Genaxxon Bioscience, Ulm, Germany). PCR products were
separated using agarose gel electrophoresis and visualized
after staining with GelRed (Genaxxon Bioscience). Images
were captured using a Biometra (Göttingen, Germany) gel
documentation station. Quantitative RT-PCR was performed
using the MyiQTM system (Bio-Rad, München, Germany)
in combination with the Quantitect SYBR Green PCR Kit
(Applied Biosystems, Darmstadt, Germany). 1 µl of cDNA
template was used in 25 µl reaction mixture. Results were
analyzed using the Bio-Rad iQ5 Optical System Software and
the comparative CT method. All data are expressed as 2−11CT
for the gene of interest normalized to the housekeeping gene
Gapdh and presented as fold change relative to controls.
The following primers have been used throughout this study:
Arg1for 5′- AACACTCCCCTGACAACCAG-3′, Arg1rev 5′-CT
GAAAGGAGCCCTGTCTTG-3′ [NM_007482.3], Igf1for 5′-C
TGGACCAGAGACCCTTTGC-3′, Igf1rev 5′-GGACGGGGACT
TCTGAGTCTT-3′ [NM_010512], IL4for 5′-ATTTTGAACGAG
GTCACAGGAGAAG-3′, IL4rev 5′-ACCTTGGAAGCCCTACA
GACGAG-3′ [NM_021283.2], Gapdhfor 5′-GGCATTGCTCTC
AATGACAA-3′, Gapdhrev 5′-ATGTAGGCCATGAGGTCCAC-
3′[NM_001289726].
ELISA
Interleukin 4 was detected in serum-free culture medium from
E14 mixed neuron-glia cultures from control and MPP+-treated
groups after 48 h as well as in medium from primary microglia
cultures from control and MPP+-treated groups after 24 h
using the murine IL4 ELISA Development Kit (Peprotech,
Hamburg, Germany). IGF-1 was detected in serum-free culture
medium from control IL4-treated primary microglia cultures
using the murine IGF-1 ELISA Development Kit (Peprotech).
ELISAs were performed according to the manufacturer’s
instructions. Color reactions were performed using 2,2 azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid) substrate (ABTS,
Sigma-Aldrich, Germany) for 30 min in the dark. Finally,
absorbance was detected using Multiskan FC plate reader
(Thermo Fischer) at the absorption of 405 nm. Concentrations
of IL4 and IGF-1 were calculated from standard curves using the
GraphPad Prism5 software (GraphPad Software Inc.).
Immunohistochemistry and
Immunocytochemistry
Numbers of tyrosine hydroxylase (TH) positive neurons in E14
ventral midbrain neuron-enriched as well as mixed neuron-
glia cultures were determined after immunocytochemistry.
After incubation of neuron cultures for different time points,
coverslips were washed once with PBS and fixed using 4%
paraformaldehyde in PBS for 15 min at room temperature (RT).
Cells were washed three times with PBS for 5 min each, and
subsequently blocked and permeabilised for 1 h at RT in PBS
containing 10% normal goat serum (Invitrogen, Darmstadt,
Germany) and 0.1% Triton-X-100 (Roche Diagnostics). Primary
antibodies rabbit anti-TH (1:1.000, polyclonal, Millipore,
Schwalbach, Germany), anti-Iba1 (1:500, polyclonal, Wako)
and anti-Gfap (1:800, monoclonal, Millipore) were incubated
overnight at RT. Afterward, coverslips were washed three
times with PBS, and cells were incubated with goat-anti-
rabbit peroxidase-conjugated secondary antibodies (1:500,
Nordic Immunology) for 1 h at RT. The immunoreactivity was
visualized using diaminobenzidine (Sigma-Aldrich, Deisenhofen,
Germany) as described by Adams (1981). Tile scans from whole
coverslips were obtained using an Zeiss AxioImager M2 (Zeiss,
Göttingen, Germany) and cell counting was performed using
ImageJ software (NIH). Immunofluorescent stainings were
performed using fixed cultures on glass coverslips as mentioned
above, followed by incubation with goat anti-mouse or goat
anti-rabbit fluorescence-coupled secondary antibodies (1:200,
Cell Signaling Technologies) for 1 h at RT. The sections
were then washed three times with PBS for 3 min each and
nuclei were counterstained using 4′,6-diamidino-2-phenylindole
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(DAPI, Roche). After a final washing step, sections were
placed on objective slides and mounted with Fluoromount G
mounting medium (SouthernBiotech). Fluorescence images
were captured using the Zeiss AxioImager M2 (Zeiss, Göttingen,
Germany).
Unbiased Stereology
Numbers of TH+ mDA neurons, Iba1+ microglia and Gfap+
astrocytes were estimated according to the optical fractionator
methods using the Stereo Investigator software (MBF Bioscience,
Germany). Cell counting was performed using an oil immersion
63 × objective (AxioImager M1, Zeiss, Göttingen, Germany),
counting frame of 50 µm × 50 µm and a grid size of
120 µm × 100 µm. The optical fractionator was optimized to
reach a coefficient of error ≤0.1. For each animal four sections
with an evaluation interval of three were selected and labeled
cells were counted. The nucleus of each immunoreactive cell was
chosen as the counting event. Cell numbers are either presented
as total estimated cell numbers or percentages (MPTP model)
compared to PBS-treated control animals.
HPLC-Based Quantification of Striatal
Dopamine Levels
Dopamine levels were quantified as recently described (Machado
et al., 2016a). Striatal tissues were dissected (Bregma 1.32-
0) at 7 and 90 days after MPTP injections, weighted and
transferred to ice-cold 0.2 M perchloric acid (40 µl/mg tissue).
Samples were homogenized in 0.2 M perchloric acid using a
Precellys 24 tissue homogenizer (Peqlab, Germany). HPLC-ED
was performed as described recently (Schneider et al., 2011).
Briefly, homogenates were centrifuged at 20.000 × g for 5 min
at 4◦C and filtered through 0.2 µm filters. DA concentrations
were detected using a HPLC pump (UltiMate 3000 Quaternary
Analytical, Dionex), an autosampler (WISP 717plus, Waters,
Germany) and an amperometric detector (Antec Intro, Antec
Leyden, Netherlands). The isocratic mobile phase consisted of
sodium acetate (90 mM), citric acid monohydrate (60 mM),
ethylene- diaminetetraacetic acid (2 mM), 1-octanesulfonic
acid (3 mM), and 8% methanol and was adjusted to a pH
of 5.3. DA was separated on a Prontosil 120-3-C18 AQ
column (3 µm, 120 × 2 mm; Bischoff chromatography,
Germany) by using a fixed flow rate of 300 µl/min. Data
were registered and analysed by using Chromeleon 6 software
(Dionex).
Statistics
Data are given as means ± standard error of the mean (SEM).
Statistical differences between two groups were determined
using Student’s t-test. Normality of samples was assessed
using the D’Agostino and Pearson omnibus normality test (as
recommended by GraphPad Prism) and non-parametric tests
have been used where appropriate. Multiple-group analysis was
performed using one-way ANOVA followed by Bonferroni’s
multiple comparison post-test. P-values ≤0.05 were considered
as statistically significant. All statistical analyses were performed
using the GraphPad Prism5 software (GraphPad Software Inc.).
RESULTS
IL4 Protects mDA Neurons from
MPP+-Induced Degeneration in the
Presence of Glia Cells
In order to address the neuroprotective potential of IL4
against MPP+-induced mDA neurodegeneration, E14 ventral
midbrain cultures were treated for 48 h with MPP+ (0.2 µM)
in the absence or presence of recombinant IL4 (10 ng/ml).
Figures 1A,B demonstrates that neuron-enriched cultures
responded to MPP+ application with a significant loss of mDA
neurons (39.39%± 7.821). IL4 co-treatment was not sufficient to
protect mDA neurons in neuron-enriched cultures from MPP+-
induced neurodegeneration (40.59% ± 7.417). Next, mDA
neurodegeneration was induced by MPP+ in mixed neuron-glia
cultures. As shown in Figures 1C,D, MPP+ treatment alone
resulted in a significant decrease of mDA neurons in mixed
neuron-glia cultures (54.93% ± 6.361). Interestingly, IL4 co-
treatment significantly increased the survival of mDA neurons
in mixed neuron-glia cultures (77.98% ± 4.655). These results
indicate that IL4 only exerts its neuroprotective effects against
MPP+-induced neurodegeneration in the presence of glia cells.
Neutralization of IL4 Increases
MPP+-Induced Neurodegeneration In
vitro
Since IL4 has been recently described to be expressed by microglia
(Park et al., 2005), we analyzed whether IL4 is expressed in
the used E14 mixed neuron-glia culture system. Whereas Gfap+
astrocytes were negative for IL4, microglia labeled with FITC-
coupled tomato lectin displayed a strong immunoreactivity for
IL4 (Figure 2A). Using an IL4 ELISA, we further analyzed the
levels of IL4 in supernatants of control- and MPP+-treated
cultures. Figure 2B demonstrates that 0.821 ng/ml ( ± 0.179)
IL4 was detectable after 48 h in supernatants from control
cultures and a slight but not significant increase of IL4 levels
(1.123 ng/ml ± 0.5164) could be determined after treatment
with MPP+. Moreover, we addressed whether primary microglia
respond to MPP+ treatment with changes in IL4 secretion.
24 h after treatment with MPP+ no change in IL4 secretion
from primary microglia cultures was detectable. Interestingly, the
data demonstrate that microglia in mixed neuron-glia cultures
release higher levels of IL4 than primary microglia. We next
aimed to inhibit endogenous IL4 in mixed-neuron glia cultures
in order to determine the role of microglia-derived IL4 during
MPP+-induced neurodegeneration. Thus, the functionality of a
neutralizing IL4 antibody (IL4 nAB) was validated. Therefore,
primary microglia cultures were treated with recombinant IL4
(10 ng/ml) in the presence or absence of IL4 nAB at dilutions
of 1:100 and 1:50, respectively. Using semiquantitative RT-PCR,
expression of the IL4-induced M2 marker Arg1 was analyzed. As
shown in Figure 2C, Arg1 expression was induced after treatment
of primary microglia with IL4 for 24 h. Almost complete
abrogation of IL4-triggered Arg1 expression was observed in the
presence of the IL4 nAB at a dilution of 1:50, which was used
for further IL4 neutralization experiments. Next, mixed-neuron
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FIGURE 1 | Interleukin 4 (IL4) protects midbrain dopaminergic (mDA) neurons from MPP+-induced neurodegeneration in mixed neuron-glia cultures.
E14 ventral midbrain neuron-enriched cultures (A) and E14 ventral midbrain mixed neuron-glia cultures (C) were treated with 0.2 µM MPP+ in the presence or
absence of IL4 (10 ng/ml) for 2 days and numbers of TH+ neurons were counted. Scale bars indicate 50 µm. Quantifications and statistical evaluations revealed that
IL4 failed to protect mDA neurons in E14 neuron-enriched cultures (B) but was sufficient to significantly protect mDA neurons in E14 mixed neuron-glia cultures (D).
Data are given as mean ± SEM from four (neuron-enriched cultures) and five (neuron-glia cultures) independent experiments performed in duplicates. P-values
derived from one-way ANOVA followed by Bonferroni’s multiple comparison post-test are ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
glia cultures were treated with MPP+ and endogenous IL4 was
blocked (IL4 nAB, 1:50). Figures 2D,E show that inhibition
of endogenous IL4 resulted in a significant increase in MPP+-
induced neurodegeneration (38.75 % ± 6.116) as compared to
MPP+ treatment alone (54.08% ± 4.72). These data clearly
demonstrate that microglia-derived IL4 in mixed-neuron glia
cultures is important to protect mDA neurons from MPP+
intoxication.
Conditioned Medium from IL4-Treated
Primary Microglia Promotes Survival of
mDA Neurons
The abovementioned results indicate that IL4 might shape the
functions and properties of microglia in mixed neuron-glia
cultures to promote survival of mDA neurons. Hence, primary
microglia were treated with IL4 and secretion of cytokines and
chemokines were analyzed. As shown in Figure 3A, results
of the array using the proteome profiler kit for inflammatory
cytokines revealed that IL4 did not influence the secretion
of the vast majority of cytokines/chemokines from microglia.
Notably, MCP-5 and MIP2 were two candidates with increased
secretion after IL4 treatment (10 ng/ml) for 24 h. We further used
microglia-conditioned medium to treat E14 neuron-enriched
cultures in order to determine the survival promoting effects
of microglia-derived factors on mDA neurons. Figures 3B,C
show that microglia-conditioned medium after treatment with
IL4 for 24 h (MCM IL4) significantly increased mDA neuron
survival (157.4% ± 11.13) compared to microglia control
medium (MCM). The observed neuroprotective effect of MCM
IL4 was not promoted by IL4 itself, since direct IL4 treatment
of E14 neuron-enriched cultures did not result in an increase
of surviving TH+ neurons (108.5% ± 2.849). This observation
demonstrates that IL4 treatment of microglia induces the
secretion of neuroprotective factors, which increase the survival
of TH+ neurons in E14 neuron-enriched cultures. IGF-1 has
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FIGURE 2 | Neutralization of endogenous IL4 increases MPP+-induced neurodegeneration in vitro. (A) Cellular expression of IL4 in E14 mixed neuron-glia
cultures was determined after co-staining with Gfap as an astrocyte marker and FITC-coupled tomato lection as a microglia marker. White arrows mark IL4+ cells.
Scale bar indicates 30 µm. (B) Secretion of IL4 in E14 mixed neuron-glia cultures under control conditions and 2 days after MPP+ treatment was determined using
an IL4 ELISA. The levels of secreted IL4 in supernatants of primary microglia cultures 24 h after MPP+ treatment (0.2 µM) was analyzed using an IL4 ELISA.
(C) Validation of IL4 neutralization in vitro. Primary microglia cultures were treated with recombinant IL4 (10 ng/ml) in the presence (1:50 and 1:100) or absence of an
IL4 neutralizing antibody and IL4-mediated increase of Arg1 expression was assessed by PCR. Gapdh was used as housekeeping gene. (D) E14 ventral midbrain
mixed neuron-glia cultures were treated with 0.2 µM MPP+ in the presence or absence of an IL4 neutralizing antibody (IL4nAB) at a dilution of 1:50 for 2 days and
numbers of TH+ neurons were counted. Scale bars indicate 50 µm. (E) Quantifications and statistical evaluation demonstrates that neutralization of IL4 increases
MPP+-induced degeneration of mDA neurons in vitro. Data are given as mean ± SEM from six (B) and three (D,E) independent experiments performed in
duplicates. P-values derived from one-way ANOVA followed by Bonferroni’s multiple comparison post-test are ∗∗p < 0.01 and ∗∗∗p < 0.001.
been identified as a survival-promoting factor secreted by
macrophages after IL4 treatment (Wynes et al., 2004). Therefore,
we analyzed whether IL4 treatment of primary microglia
increases expression and secretion of IGF-1. Using quantitative
RT-PCR, we observed that IGF-1 mRNA levels increased after
IL4 treatment, reaching a significant peak after 12 h of treatment
(Figure 3D). Moreover, Figure 3E clearly demonstrates that
secretion of IGF-1 from primary microglia was significantly
increased after 24 h (4.919 ng/ml ± 0.2868) compared to
untreated control cells (2.061 ng/ml ± 0.3321). As IL4 was
able to protect TH+ neurons from MPP+-induced degeneration
in mixed neuron-glia cultures, we wanted to address whether
microglia-derived IGF-1 was responsible for this protective effect.
Thus, recombinant IGF-1 was used in order to determine
whether TH+ neurons in E14 neuron-enriched cultures could be
protected from MPP+-induced neurodegeneration. As shown in
Figure 3F, MPP+ treatment significantly reduced the numbers
of TH+ neurons (38.2% ± 9.848) and a slight non-significant
increase of neuron numbers in the presence of IGF-1 could be
observed. Although IGF-1 was able to increase the survival of
mDA neurons in the presence of MPP+ (56.24% ± 10.39), the
protective effect did not reach significance. Together, these results
indicate that IL4 treatment of primary microglia results in the
release of protective factors including IGF-1, which might at least
partially mediate the neuroprotective properties of microglia-
conditioned medium.
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FIGURE 3 | Microglia-conditioned medium after IL4 treatment is neuroprotective in vitro. (A) Treatment of primary microglia with recombinant IL4 (10 ng/ml)
for 24 h results in modest changes of secreted chemokines and cytokines. As expected, IL4 was detected in IL4-treated samples and thus was not included in the
densitometric spot analysis. Levels of MCP-5 and MIP-2 were increased after IL4 treatment. Data are given as mean ± SEM from two independent experiments.
(B) E14 ventral midbrain neuron-enriched cultures were treated for 2 days with serum-free medium (control) and IL4 (10 ng/ml) or with microglia conditioned medium
obtained after treatment of primary microglia for 24 h with serum-free medium (MCM) and IL4 at 10 ng/ml (MCM IL4). Scale bar indicates 50 µm. (C) Quantifications
of TH+ neurons indicate that microglia conditioned medium after treatment with IL4 (MCM IL4) significantly increased neuron survival. IL4 alone was not able to
promote neuroprotection. (D) IL4 treatment increases IGF-1 expression in primary microglia. After treatment for 3, 6, 12, and 24 h IGF-1 expression was determined
using qPCR and is presented as fold change compared to untreated control cultures. Significant increases in IGF-1 expression was observed after 12 h. (E) IGF-1
secretion under control conditions and 24 h after treatment with IL4 (10 ng/ml) was detected using an IGF-1 ELISA. (F) Recombinant IGF-1 (50 ng/ml) increased
neuron survival in E14 ventral midbrain neuron-enriched cultures without reaching significance. Data are given as mean ± SEM from four (B–D), three (C, ELISA) and
five (E) independent experiments performed in duplicates. P-values derived from student’s t-test (D) are ∗p < 0.05 and ∗∗p < 0.01. P-values derived from one-way
ANOVA followed by Bonferroni’s multiple comparison post-test are ∗p < 0.05 and ∗∗p < 0.01.
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FIGURE 4 | Knockout of IL4 has no effect on the cellular composition of the nigrostriatal system. Changes in numbers of TH+ neurons (A,B), Iba1+
microglia (C,D,E,I,J) and Gfap+ astrocytes (F,G,H,K,L) in the nigrostriatal system were analyzed in 4 months old male WT and IL4 KO mice using unbiased
stereology. A significant change in cell numbers was only detected for Iba1+ microglia in the SNpc, which were reduced in IL4 KO mice. Scale bar indicates 200 µm.
Data are given as mean ± SEM from at least three animals per genotype. P-values derived from student’s t-test are ∗p < 0.05. VTA, ventral tegmental area; SNpc,
substantia nigra, pars compacta; SNpr, substantia nigra, pars reticularis; CC, corpus callosum; CPu, caudate putamen.
Normal Morphology and Cellular
Composition of the Nigrostriatal System
in IL4-Deficient Mice
In order to address the role of endogenous IL4 during MPTP-
induced degeneration of mDA neurons in vivo, IL4-deficient
mice were used. IL4 KO mice are viable and fertile, develop
normally and show no phenotypical abnormalities. However,
these mice show impaired secretion of IL5 and IL10 and reduced
IL4-dependent expression of IgE and IgG1 (Metwali et al.,
1996). As a prerequisite for the use of IL4 KO mice in the
MPTP model, we first analyzed the cellular composition of the
nigrostriatal system in adult mice. Therefore, 4 months old
mice were perfused and brains were cut into 50 µm coronal
sections, which were subsequently used for TH-, Iba1- and Gfap-
immunohistochemistry. Cell numbers were determined using
unbiased stereology. As shown in Figures 4A,B, the numbers of
TH+ mDA neurons in the substantia nigra pars compacta (SNpc)
were not altered in IL4-deficient mice. Quantification of Iba1+
microglia in SNpc and SNpr revealed a slight and significant
decrease in microglia numbers in SNpc (Figures 4C,E) but no
impairment of Iba1+ microglia numbers in SNpr (Figures 4D,E).
Analysis of Gfap+ astrocytes showed that the numbers of reactive
astrocytes are neither changed in the SNpc, nor in the SNpr
(Figures 4F–H). Similar results were obtained to the basal ganglia
(CPu). The numbers of Iba1+ microglia in the CPu of IL4 KO
mice were comparable to WT mice (Figures 4I,J). Numbers of
Gfap+ astrocytes in the CPu were increased in IL4 KO mice
without reaching statistical significance (Figures 4K,L). These
data indicate that loss of IL4 does not impair development and
maintenance of the nigrostriatal system in vivo.
Loss of IL4 Does Not Alter the
Susceptibility toward MPTP-Induced
Neurodegeneration
Since endogenous IL4 was sufficient to protect mDA neurons
from MPP+-induced neurodegeneration in vitro, we used the
MPTP mouse model to address the role of IL4 in this model
for PD in vivo. Figure 5A displays the injection scheme and
the time points used for RNA isolation, immunohistochemistry,
and analysis of DA levels using HPLC. We first determined the
expression of IL4 in the MPTP model. As shown in Figure 5B,
a slight but not significant increase in IL4 expression was
observed in the SN 1 day after MPTP injection. All other
time points analyzed revealed no increases in IL4 expression
in SN or CPu after intoxication with MPTP. Noteworthy,
the relatively high CT values (between 32–36) indicate that
in contrast to E14 mixed neuron-glia cultures, IL4 is hardly
expressed in the nigrostriatal system in vivo. Two different time
points for analysis of TH+ neuron numbers and striatal DA
levels were chosen according to the acute neurodegeneration
phase (7 days) and the regeneration phase (90 days) of this
model (Machado et al., 2016c). Figures 5C,E demonstrate that
numbers of TH+ neurons were significantly reduced in both
WT (57.4% ± 7.895) and IL4 KO mice (56.67% ± 14.39)
without showing significant differences between both genotypes.
Similar results were obtained after analysis of striatal DA levels.
IL4 KO mice displayed a significant reduction of DA levels
(46.4% ± 10.51) comparable to WT mice (49.21% ± 3.72,
Figure 5D). Analysis of neuron numbers and DA levels 90 days
after MPTP administration revealed that WT and IL4 KO
mice showed a similar restoration of the MPTP-intoxicated
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FIGURE 5 | Lack of IL4 has no impact on the susceptibility toward 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration.
(A) Scheme for MPTP injections and time points used for qPCR, HPLC and immunohistochemistry. (B) Expression of IL4 in total tissue samples from substantia
nigra (SN) and caudate putamen (CPu) of wild type (WT) mice 1 and 2 days after MPTP injections. qPCR results were normalized to Gapdh and are given as fold
changes (n = 3 PBS, n = 3 MPTP). (C) Immunohistochemical detection of TH+ neurons in the SN 7 days after injections with PBS and MPTP. Scale bar indicates
300 µm. (D) Striatal dopamine levels in PBS- and MPTP-injected mice after 7 days. Equal reductions in dopamine levels were observed in both genotypes.
(E) Quantification of TH+ neuron numbers in the SN of PBS- and MPTP-injected mice. No significant changes in neurodegeneration were detected between WT and
mutant (IL4 KO) mice. (F) Immunohistochemical detection of TH+ neurons in the SN 90 days after injections with PBS and MPTP. (G) Striatal dopamine levels in
PBS- and MPTP-injected mice after 90 days. Similar recoveries of dopamine levels were observed in WT and IL4 KO mice. (H) TH+ neuron numbers in the SN of
PBS- and MPTP-injected mice after 90 days were not significantly different between WT and IL4 KO mice, indicating normal regeneration of mDA neurons in
IL4-deficient mice. Scale bars indicate 300 µm. Data are given as mean ± SEM from at least three mice per genotype and time point. P-values derived from
one-way ANOVA followed by Bonferroni’s multiple comparison post-test are ∗p < 0.05 and ∗∗p < 0.01.
nigrostriatal system. As shown in Figures 5F,H, numbers of mDA
neurons in the SNpc recovered similarly in WT (84.82%± 10.86)
as well as in IL4 KO mice (93.29% ± 10.4). Moreover, striatal
DA levels increased in both genotypes (WT: 79.87% ± 4.956,
IL4 KO: 82.14% ± 1.976) compared to 7 days after intoxication,
but were still significantly reduced at 90 days compared to
PBS-injected control mice (Figure 5G). Taken together, these
data demonstrate that loss of endogenous IL4 does not increase
the susceptibility toward MPTP-induced degeneration of mDA
neurons in vivo. Moreover, the regeneration of the nigrostriatal
system after MPTP administration is not impaired in IL4 KO
mice, indicating that endogenous IL4 is dispensable in the MPTP
mouse model for PD.
DISCUSSION
In the present study, we have demonstrated that exogenous IL4
protects mDA neurons from MPP+-induced degeneration in the
presence of glia cells in vitro. Moreover, we provide evidence that
endogenous microglia-derived IL4 in mixed neuron-glia cultures
is important to reduce mDA neurodegeneration after MPP+
application and might facilitate neuroprotection by regulating
microglia-mediated secretion of neuroprotective factors such
as IGF-1. In vivo, the expression of IL4 was hardly detectable
under basal conditions or after MPTP administration, and the
loss of IL4 did not alter the susceptibility of mDA neurons
toward MPTP-induced degeneration. Moreover, the regeneration
of the nigrostriatal system after MPTP intoxication, as evident by
restoration of TH+ neuron numbers as well as striatal DA levels,
was not impaired in IL4-deficient mice.
Interleukin 4 has been described to promote a microglia
activation state, which is characterized by functional features such
as tissue repair and cellular protection (Colton and Wilcock,
2010). Here, we have demonstrated that microglial expression
and secretion of cytokines/chemokines is not dramatically
altered after IL4 treatment and thus, the neuroprotective effects
for TH+ neurons seem to be mediated by other microglia-
derived factors. However, IL4 has been reported to induce
IL6-producing macrophages that inhibit neuroinflammation
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in vitro and in vivo (Casella et al., 2016). Interestingly,
IL6 is able to protect mDA neurons from MPP+-driven
degeneration (Spittau et al., 2012) and reduced expression
of IL6 has been linked to increased degeneration of mDA
neurons after treatment of GDF15-deficient mice with 6-
OHDA (Machado et al., 2016b). Nevertheless, IL6 was not
regulated after treatment of microglia with IL4 in the cell
culture model used in this study. Another molecular mechanism
to explain IL4-mediated neuroprotection in mixed neuron-
glia cultures is the regulation of microglia function via the
CD200/CD200R ligand/receptor pair. Whereas neurons express
CD200, expression of CD200R is restricted to myeloid cells
including microglia and binding of CD200 to its cognate receptor
reduces microglia activation (Barclay et al., 2002). IL4 has
been shown to modulate these interactions by increasing the
surface expression of CD200R in microglia (Lyons et al., 2007).
Moreover, lack of CD200 results in increased microglia activation
after facial nerve transection (Hoek et al., 2000) indicating the
importance of this neuron-microglia communication. However,
in the present study we observed that microglial conditioned
medium after IL4 stimulation is neuroprotective without the
physical presence of microglia. This observation suggests that
microglia secrete neurotrophic factors after IL4 treatment,
which is at least partially responsible for the protection
of mDA neurons. We identified IGF-1 as one of these
neurotrophic factors and Wynes et al. (2004) have described IL4-
mediated upregulation of IGF-1 in macrophages. Interestingly,
IGF-1 has been reported to protect mDA neurons in PD
models in vivo. IGF-1 increased survival of TH+ neurons
and reduced neuroinflammation after intoxication with MPTP
(Nadjar et al., 2009) as well as after 6-OHDA injections
(Guan et al., 2000). We further tried to rescue mDA neurons
from MPP+-induced degeneration, by adding recombinant
IGF-1 to neuron-enriched cultures. Although the number of
surviving neurons increased, the protection was not as effective
as IL4 treatment of mixed neuron-glia cultures. It is high
likely that microglia-derived neurotrophic factors and neuron–
microglia interactions contribute to the neuroprotective effects
observed after IL4 application in neuron-glia cultures. The
fact that IL4 secretion from microglia is not a direct effect
of MPP+ suggests that challenged neurons in mixed neuron-
glia cultures trigger IL4 release from microglia. Damaged
neurons have been shown not be passive targets of microglia-
mediated neurotoxicity but are capable of regulating microglia
functions. Release of CX3CL1 or IL34 from neurons and the
subsequent binding to microglia-specific receptors CX3CR1
and CSF1R are well described mechanisms to shape microglia
functions toward a neuroprotective phenotype (Suzumura, 2013).
Such neuron–microglia interactions might also be responsible
for the IL4 release observed in mixed-neuron glia cultures
in the present study and should be further analyzed to
understand how MPP+-challenged neurons regulate microglia
functions.
In vitro, neutralization of endogenous IL4, expressed by
microglia, worsens MPP+-induced degeneration of mDA
neurons. This result suggests that IL4 acts in an autocrine
manner on microglia in order to silence their activation. In
vivo, loss of IL4 did not change the extent of neurodegeneration
and neuroregeneration, indicating that IL4 is dispensable
in the MPTP mouse model for PD. One of the reasons for
these observations, might be the fact that IL4 expression
in the nigrostriatal system is hardly detectable under basal
conditions as well as after MPTP intoxication. The main cell
type expressing IL4 are Th2 T-cells (Bao and Reinhardt, 2015).
However, myeloperoxidase-positive neutrophils after spinal
cord injury (Lee et al., 2010) and also damaged neurons (Zhao
et al., 2015) are able to express IL4 under neuropathological
conditions. The MPTP mouse model for PD is characterized
by a distinct leakage of the blood-brain-barrier (BBB) and a
modest infiltration of CD3+ T-cells (Chung et al., 2013) but
the neuroinflammatory response is predominantly performed
by brain-resident microglia (Depboylu et al., 2012). This
is in contrast to the BBB impairment observed in the 6-
OHDA mouse model for PD, where a pronounced invasion
of T-cells and B-cells have been described which makes this
model more suitable to study the contribution of adaptive
immune responses during mDA degeneration (Theodore
and Maragos, 2015). Lack of appropriate numbers of IL4-
expressing T-cells might explain why the extent of mDA
neurodegeneration induced by MPTP was not altered in
IL4-deficient mice used in the present study. The potential
of CD4+ T-cells to protect mDA neurons from MPTP-
induced neurodegeneration has been described after adoptive
transfer of CD4+/CD25+ regulatory T-cells (Reynolds et al.,
2007) and highlight the therapeutic options of these anti-
inflammatory cells. It would be of major interest to address
the role of endogenous IL4 in the 6-OHDA mouse model for
PD, where the involvement of adaptive immune responses
has been clearly demonstrated. Moreover, it has to be taken
into account that alternative microglia activation in PD
models as evidenced by expression of M2-like markers such
as Ym1 and Arg1 (Haas et al., 2016) might be regulated
by IL4-independent mechanisms. Contact to apoptotic cells
and subsequent release of microglial TGFβ1 and TGFβ2
resulting in increased expression of the M2-like marker
Arg1 has been described (Spittau et al., 2015). Microglial
TGFβ-signaling seems to be essential for promoting alternative
microglia activation (Zhou et al., 2012) and could be one
mechanism to trigger IL4-independent M2-like microglia
activation.
The therapeutic potential of exogenous IL4 has been well
documented in several CNS pathology models including models
for spinal cord injury (Lee et al., 2010; Francos-Quijorna et al.,
2016), APP/PS1 transgenic mice (Kiyota et al., 2010), cerebral
ischemia (Zhao et al., 2015; Liu et al., 2016) as well as multiple
sclerosis (Butti et al., 2008). In these studies, IL4 was either
injected or overexpressed in CNS tissues and promoted strong
neuroprotective and anti-inflammatory effects. It has been shown
that a heterogeneous induction of the microglia M2a phenotype
was observed after central administration of IL4 and contributes
to neuroprotection (Pepe et al., 2014). However, further studies
have to be performed in order to determine the potential of
exogenous IL4 in animal models for PD including MPTP and
6-OHDA.
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Taken together, the results presented in this study demonstrate
that IL4 is able to shape microglia functions to promote survival
of mDA neurons. We provided evidence that endogenous IL4 is
dispensable for MPTP-induced neurodegeneration in vivo but the
presence of IL4 in vitro is important to limit degeneration of TH+
neurons after MPP+ intoxication. Our results strengthen the
hypothesis that IL4-treated microglia are capable of facilitating
protection of mDA neurons and underline the therapeutic
potential of IL4 administration in models of PD.
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